AstraZeneca vs Volkswagen: Founders, CEOs and History
AstraZeneca was founded in 1999 by Sir David Barnes, Håkan Mogren and is led by Pascal Soriot. Volkswagen was founded in 1937 by Ferdinand Porsche and is led by Oliver Blume.
Company facts
AstraZeneca
- Founded
- 1999
- Headquarters
- Cambridge, England
- Current CEO
- Pascal Soriot
- Employees
- 96,100
Volkswagen
- Founded
- 1937
- Headquarters
- Wolfsburg, Germany
- Current CEO
- Oliver Blume
- Employees
- 663,000
Founders
AstraZeneca
Sir David Barnes
Sir David Barnes was chief executive of Zeneca Group plc, the company created when Imperial Chemical Industries demerged its pharmaceuticals, agrochemicals and specialty chemicals businesses in 1993, and he led the Zeneca side of the negotiations that produced…
Håkan Mogren
Håkan Mogren was chief executive of Astra AB and negotiated the Swedish side of the 1999 merger with Zeneca Group alongside Sir David Barnes.
Volkswagen
Ferdinand Porsche
Ferdinand Porsche (1875-1951) was an Austrian-born automotive engineer who had worked for Lohner, Austro-Daimler and Daimler-Benz before opening his own design office in Stuttgart in 1931.
CEOs and their tenures
AstraZeneca
- Tom McKillop1999–2006
Chief Executive Officer
McKillop led AstraZeneca from the 1999 merger through the Nexium launch and the first biotech acquisitions.
Source - David Brennan2006–2012
Chief Executive Officer
Brennan led AstraZeneca through the start of the patent cliff and favoured cost-cutting and share buybacks over pipeline investment.
Source - Pascal Soriot2012–present
Chief Executive Officer
Soriot took over a company whose revenue was falling toward $25.7 billion and has taken Total Revenue to $58.7 billion, with 16 blockbuster medicines.
Source
Volkswagen
- Hermann Münch1946–1947
Chief Executive Officer
Early executive involved in the incredibly complex immediate post-war administration of the completely destroyed factory under British military control.
Source - Heinrich Nordhoff1948–1968
Chief Executive Officer
The absolute legendary post-war architect who took the ruins of the VW factory and transformed the Beetle into a massive, globally beloved cultural icon and economic miracle.
Source - Kurt Lotz1968–1971
Chief Executive Officer
Early post-war leader who began the critical process of diversifying VW's lineup beyond relying entirely on a single model (the Beetle).
Source - Rudolf Leiding1971–1975
Chief Executive Officer
Crucial CEO who managed the extremely difficult, highly risky transition away from the iconic but severely outdated Beetle toward modern, front-wheel-drive water-cooled cars (like the Golf).
Source - Toni Schmücker1975–1982
Chief Executive Officer
Guided the company through the severe financial crises of the 1970s, ensuring the successful launch and massive adoption of the original VW Golf.
Source - Carl Hahn1982–1993
Chief Executive Officer
As CEO in the 1980s, he executed the massive, highly strategic acquisitions of SEAT and Skoda, laying the foundation for VW's absolute dominance in Europe.
Source - Ferdinand Piëch1993–2002
Chief Executive Officer
As the legendary, absolutely ruthless patriarch (and grandson of Ferdinand Porsche), he transformed VW from a struggling mass-market brand into the most powerful automotive conglomerate on Earth.
Source - Bernd Pischetsrieder2002–2006
Chief Executive Officer
Serving as CEO from 2002 to 2006, he oversaw the incredibly complex integration of massive luxury brands like Bugatti and Bentley into the VW Group portfolio.
Source - Martin Winterkorn2007–2015
Chief Executive Officer
As the notoriously demanding, absolutely feared CEO, he oversaw massive global expansion but fostered a culture of absolute terror that led engineers to cheat rather than admit failure.
Source - Matthias Müller2015–2018
Chief Executive Officer
As CEO during the darkest period in modern VW history, he initiated the massive cultural purge of the toxic, highly secretive engineering culture that caused the cheating scandal.
Source - Herbert Diess2018–2022
Chief Executive Officer
Serving as CEO, he forcefully dragged the massive, highly bureaucratic legacy automaker into the Tesla era, though his abrasive style alienated the powerful Porsche-Piëch families.
Source - Oliver Blume2022–present
Chairman of the Board of Management
He also ran Porsche AG alongside the group role until Michael Leiters took over as Porsche CEO on January 1, 2026, leaving Blume focused on Volkswagen Group.
Source
Timeline: AstraZeneca and Volkswagen side by side
1913AstraZeneca
Astra AB Founded in Södertälje, Sweden
400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.
1937Volkswagen
Volkswagen founded
Volkswagen was founded under the German Labour Front as part of a state-directed people's car program.
1945Volkswagen
Wolfsburg restarted
British military administration helped restart peacetime production at Wolfsburg after World War II.
1965Volkswagen
Audi foundation added
Volkswagen acquired Auto Union from Daimler-Benz, creating the foundation for modern Audi.
1974Volkswagen
Golf production begins
The Golf gave Volkswagen a modern front-engine, front-wheel-drive compact platform after the Beetle era.
1993AstraZeneca
Zeneca Group Spun Off from ICI
Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.
1999AstraZeneca
Astra and Zeneca Merge to Form AstraZeneca
The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.
2000AstraZeneca
Nexium Launch Replaces Prilosec
AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.
2006AstraZeneca
Acquisition of Cambridge Antibody Technology
AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.
2007AstraZeneca
Acquisition of MedImmune for $15.6 Billion
AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.
2012AstraZeneca
Pascal Soriot Appointed CEO
Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.
2012Volkswagen
Porsche consolidated
Porsche became a controlled sport-luxury profit anchor within Volkswagen Group.
2014AstraZeneca
Pfizer Hostile Takeover Rejected
AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.
2014AstraZeneca
Acquisition of Almirall Respiratory Portfolio
AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.
2015AstraZeneca
Tagrisso Approved for EGFR-Mutated Lung Cancer
The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.
2015Volkswagen
Matthias Müller becomes CEO
Matthias Müller became CEO of Volkswagen Aktiengesellschaft in 2015. Chief executive of Volkswagen Aktiengesellschaft from 2015 to 2018.
2015Volkswagen
Emissions Scandal
US regulators accused Volkswagen in September 2015 of fitting diesel cars with software that cheated emissions tests.
2017AstraZeneca
Imfinzi Approved Based on PACIFIC Trial
The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.
2018Volkswagen
Herbert Diess becomes CEO
Herbert Diess became CEO of Volkswagen Aktiengesellschaft in 2018. Chief executive of Volkswagen Aktiengesellschaft from 2018 to 2022.
2020AstraZeneca
COVID-19 Vaccine Development with Oxford University
AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.
2021AstraZeneca
Acquisition of Alexion Pharmaceuticals for $39 Billion
AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.
2022Volkswagen
Oliver Blume becomes chairman
Oliver Blume became chairman of Volkswagen Aktiengesellschaft in 2022. He also ran Porsche AG alongside the group role until Michael Leiters took over as Porsche CEO on January 1, 2026, leaving Blume focused on Volkswagen Group.
2023AstraZeneca
CinCor Pharma Acquired for up to $1.8 Billion
AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.
2024AstraZeneca
Total Revenue Reaches $54.073 Billion
AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.
2024AstraZeneca
Fusion Pharmaceuticals and Gracell Acquisitions
AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.
2024Volkswagen
Rivian software joint venture
Volkswagen and Rivian launched a software joint venture targeting next-generation electrical architecture.
2025AstraZeneca
Total Revenue Reaches $58.739 Billion
AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.
2025AstraZeneca
EsoBiotec Acquired for Up to $1 Billion
AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.
2025AstraZeneca
$50 Billion US Manufacturing and R&D Commitment
AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.
2025Volkswagen
Revenue reaches ~$364B (EUR321.9B)
Volkswagen reported ~$364 billion (EUR321.9 billion) in sales revenue, ~$10.1 billion (EUR8.9 billion) in operating result, and 8.984 million deliveries.
2026AstraZeneca
Ordinary Shares Begin Trading on the NYSE
AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.
2026AstraZeneca
Baxfendy Approved in the US for Hypertension
The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.
2026AstraZeneca
$15 Billion China Investment Through 2030
AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.
Acquisitions
AstraZeneca
- EsoBiotec2025$1B
- Fusion Pharmaceuticals2024$2B
- Gracell Biotechnologies2024$1.2B
- CinCor Pharma2023$1.8B
- Alexion Pharmaceuticals2021$39B
- Almirall Respiratory Portfolio2014$2.1B
Volkswagen
- Porsche AG2012Undisclosed
- Bentley Motors1998Undisclosed
- Auto Union / Audi1965Undisclosed
Questions about AstraZeneca vs Volkswagen
Who is the CEO of AstraZeneca PLC and Volkswagen Aktiengesellschaft?
AstraZeneca PLC is led by Pascal Soriot and Volkswagen Aktiengesellschaft is led by Oliver Blume. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AstraZeneca PLC founded vs Volkswagen Aktiengesellschaft?
Volkswagen Aktiengesellschaft was founded in 1937 — 62 years before AstraZeneca PLC, which was founded in 1999. Volkswagen Aktiengesellschaft's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AstraZeneca PLC.
How many employees does AstraZeneca PLC have compared to Volkswagen Aktiengesellschaft?
AstraZeneca PLC employs approximately 96,100 people, while Volkswagen Aktiengesellschaft employs approximately 663,000. Volkswagen Aktiengesellschaft has the larger workforce at 663,000 employees, compared to AstraZeneca PLC's 96,100. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AstraZeneca PLC and Volkswagen Aktiengesellschaft headquartered?
AstraZeneca PLC is headquartered in United Kingdom and Volkswagen Aktiengesellschaft is headquartered in Germany. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded AstraZeneca PLC and Volkswagen Aktiengesellschaft?
AstraZeneca PLC was founded by Sir David Barnes, Håkan Mogren. Volkswagen Aktiengesellschaft was founded by Ferdinand Porsche.
Which company has a longer operating history — AstraZeneca PLC or Volkswagen Aktiengesellschaft?
Volkswagen Aktiengesellschaft has been operating for approximately 89 years, making it the more established of the two companies. AstraZeneca PLC has been in operation for around 27 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AstraZeneca vs Volkswagen overview